<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="aac"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3187007/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC3187007_files/jig.min.css"><script type="text/javascript" src="./PMC3187007_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Antimicrobial Agents and Chemotherapy"><meta name="citation_title" content="Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin"><meta name="citation_authors" content="Jee Eun Lee, Rolf van Heeswijk, Katia Alves, Frances Smith, Varun Garg"><meta name="citation_date" content="October 2011"><meta name="citation_issue" content="10"><meta name="citation_volume" content="55"><meta name="citation_firstpage" content="4569"><meta name="citation_doi" content="10.1128/AAC.00653-11"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3187007/?report=abstract"><meta name="citation_pmid" content="21825288"><meta name="DC.Title" content="Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="American Society for Microbiology (ASM)"><meta name="DC.Contributor" content="Jee Eun Lee"><meta name="DC.Contributor" content="Rolf van Heeswijk"><meta name="DC.Contributor" content="Katia Alves"><meta name="DC.Contributor" content="Frances Smith"><meta name="DC.Contributor" content="Varun Garg"><meta name="DC.Date" content="2011 Oct"><meta name="DC.Identifier" content="10.1128/AAC.00653-11"><meta name="DC.Language" content="en"><meta property="og:title" content="Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin"><meta property="og:type" content="article"><meta property="og:description" content="Telaprevir is a hepatitis C virus protease inhibitor that is both a substrate and an inhibitor of CYP3A. Amlodipine and atorvastatin are both substrates of CYP3A and are among the drugs most frequently used by patients with hepatitis C. This study was ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC3187007_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC3187007_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC3187007_files/common.min.js">//</script><script type="text/javascript" src="./PMC3187007_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC3187007_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC3187007_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC3187007_files/MathJax.js"></script><script type="text/javascript" src="./PMC3187007_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-aac.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/pdf/zac4569.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="F4FB26FC76C288610000000000177AA1"><link type="text/css" rel="stylesheet" href="./PMC3187007_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC3187007_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC3187007%2F&ncbi_pdid=article&ncbi_phid=F4FB26FC76C288610000000000177AA1'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC3187007_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3187007%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3187007%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" style="visibility: hidden;"><img src="./PMC3187007_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/82/">Antimicrob Agents Chemother</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/200756/">v.55(10); 2011 Oct</a></li><li class="accid">PMC3187007</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC3187007_files/logo-aac.gif" alt="Logo of aac" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="321,60,397,75" alt="Permissions" title="Permissions" href="http://journals.asm.org/misc/reprints.dtl" ref="reftype=publisher&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="398,60,500,75" alt="Journals.ASM.org" title="Journals.ASM.org" href="http://journals.asm.org/" ref="reftype=publisher&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="0,0,500,55" alt="Journal" title="Journal" href="http://aac.asm.org/" ref="reftype=publisher&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="48,60,118,75" alt="AAC Article" title="AAC Article" href="http://aac.asm.org/cgi/content/full/55/10/4569" ref="reftype=publisher&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7CArticle%7CFullText&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="119,60,195,75" alt="Journal Info" title="Journal Info" href="http://aac.asm.org/misc/about.dtl" ref="reftype=publisher&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="195,60,251,75" alt="Authors" title="Authors" href="http://aac.asm.org/misc/authors.dtl" ref="reftype=publisher&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="252,60,318,75" alt="Reviewers" title="Reviewers" href="http://aac.asm.org/misc/reviewers.dtl" ref="reftype=publisher&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">Antimicrob Agents Chemother. 2011 Oct; 55(10): 4569–4574. </span></div><div>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1128%2FAAC.00653-11" target="pmc_ext" ref="reftype=other&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1128/AAC.00653-11</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3187007</span></div></div></div></div></div><h1 class="content-title">Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#FN1" rid="FN1" class=" fn">▿</a></sup></h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20JE%5Bauth%5D">Jee Eun Lee</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Heeswijk%20R%5Bauth%5D">Rolf van Heeswijk</a>,<sup>2</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Alves%20K%5Bauth%5D">Katia Alves</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Smith%20F%5Bauth%5D">Frances Smith</a>,<sup>1</sup> and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Garg%20V%5Bauth%5D">Varun Garg</a><sup>1,</sup><sup>*</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id998081_ai" style="display:none"><div class="fm-affl" lang="en"><sup>1</sup>Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, Massachusetts 02139-4242</div><div class="fm-affl" lang="en"><sup>2</sup>Tibotec BVBA, Turnhoutseweg 30, Beerse, Belgium</div><div id="cor1"><sup>*</sup>Corresponding author. Mailing address: Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139-4242. Phone: (617) 444-6757. Fax: (617) 444-7166. E-mail: <a href="mailto:dev@null" data-email="moc.xtrv@grag_nurav" class="oemail">moc.xtrv@grag_nurav</a>.</div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="pmctoggle" rid="id998081_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="pmctoggle" rid="id998081_an">Article notes <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="pmctoggle" rid="id998081_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id998081_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2011 May 11; Revised 2011 Jun 23; Accepted 2011 Jul 31.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id998081_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>  © 2011, American Society for Microbiology. All Rights Reserved.</div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid419012" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid419012title" style="text-transform: uppercase;">Abstract</h2><!--article-meta--><div><p id="__p1" class="p p-first-last">Telaprevir is a hepatitis C virus protease inhibitor that is both a substrate and an inhibitor of CYP3A. Amlodipine and atorvastatin are both substrates of CYP3A and are among the drugs most frequently used by patients with hepatitis C. This study was conducted to examine the effect of telaprevir on atorvastatin and amlodipine pharmacokinetics (PK). This was an open-label, single sequence, nonrandomized study involving 21 healthy male and female volunteers. A coformulation of 5 mg amlodipine and 20 mg atorvastatin was administered on day 1. Telaprevir was taken with food as a 750-mg dose every 8 h from day 11 until day 26, and a single dose of the amlodipine-atorvastatin combination was readministered on day 17. Plasma samples were collected for determination of the PK of telaprevir, amlodipine, atorvastatin, <em>ortho</em>-hydroxy atorvastatin, and <em>para</em>-hydroxy atorvastatin. When administration with telaprevir was compared with administration without telaprevir, the least-square mean ratios (90% confidence limits) for amlodipine were 1.27 (1.21, 1.33) for the maximum drug concentration in serum (<em>C</em><sub>max</sub>) and 2.79 (2.58, 3.01) for the area under the concentration-time curve from 0 h to infinity (AUC<sub>0-∞</sub>); for atorvastatin, they were 10.6 (8.74, 12.9) for the <em>C</em><sub>max</sub> and 7.88 (6.84, 9.07) for the AUC<sub>0-∞</sub>. Telaprevir significantly increased exposure to amlodipine and atorvastatin, consistent with the inhibitory effect of telaprevir on the CYP3A-mediated metabolism of these agents.</p></div></div><div id="__sec1" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec1title" style="text-transform: uppercase;">INTRODUCTION</h2><p id="__p2" class="p p-first">Telaprevir is an orally administered inhibitor of the nonstructural 3/4A (NS3/4A) protease of the hepatitis C virus (HCV) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921859" role="button" aria-expanded="false" aria-haspopup="true">11</a>). In recent phase 3 studies of patients with chronic hepatitis C (CHC), the addition of telaprevir as part of a combination regimen with pegylated interferon and ribavirin significantly increased the rates of sustained virologic response (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921846" role="button" aria-expanded="false" aria-haspopup="true">8</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B17" rid="B17" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">17</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921856" role="button" aria-expanded="false" aria-haspopup="true">23</a>). Telaprevir was recently approved in the United States of America for the treatment of genotype 1 CHC in adult patients with compensated liver disease (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B3" rid="B3" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">3</a>).</p><p id="__p3">Amlodipine is a dihydropyridine calcium channel antagonist used to treat high blood pressure and angina or coronary artery disease. Atorvastatin is a hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor used to lower high cholesterol levels and reduce the risk of heart attack and stroke. These two drugs are frequently prescribed for patients with CHC and are commercially available as a coformulation (Caduet; Pfizer) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B1" rid="B1" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">1</a>). Both amlodipine and atorvastatin are metabolized primarily by CYP3A (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B1" rid="B1" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">1</a>). CYP3A-mediated metabolism converts atorvastatin into two major active metabolites, <em>ortho</em>-hydroxy atorvastatin and <em>para</em>-hydroxy atorvastatin, and three inactive lactone metabolites corresponding to each acid form (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B12" rid="B12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921851" role="button" aria-expanded="false" aria-haspopup="true">12</a>). Both active acid metabolites are known to be equally as potent as the parent drug and account for ∼70% of the total HMG-CoA reductase inhibitory activity of atorvastatin (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921850" role="button" aria-expanded="false" aria-haspopup="true">6</a>). Excreted primarily in the bile, atorvastatin is also a substrate for P-glycoprotein and organic anion transporter protein (OATP1B1/1B3) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B1" rid="B1" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">1</a>). Amlodipine is extensively metabolized, primarily involving oxidation to the pyridine derivative with subsequent oxidative deamination of the 2-aminoethyoxymethyl side chain or deesterification at the 5-methoxycarbonyl group. None of the metabolites have any significant calcium antagonist activity relative to amlodipine (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921844" role="button" aria-expanded="false" aria-haspopup="true">20</a>).</p><p id="__p4" class="p p-last">Telaprevir inhibits CYP3A-mediated metabolism at therapeutic concentrations and may inhibit and/or saturate P-glycoprotein in the gut. Therefore, this study was designed to evaluate the drug-drug interactions between telaprevir and amlodipine and atorvastatin in healthy volunteers.</p></div><div id="__sec2" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec2title" style="text-transform: uppercase;">MATERIALS AND METHODS</h2><div id="__sec3" class="sec sec-first"><p></p><h3 class="inline">Volunteers. </h3><p id="__p5" class="p p-first">Twenty-one healthy male (<em>n</em> = 15) and female (<em>n</em> = 6) volunteers were enrolled at the Covance Clinical Research Unit, Inc., Daytona Beach, FL. The female volunteers were documented not to have childbearing potential. At screening, the volunteers were judged to be in good health on the basis of medical history, physical examination, and routine laboratory measurement results. Volunteers had ended any short-duration courses of prescription medications, herbal medications, or dietary supplements (e.g., St. John's wort, ginkgo biloba, garlic supplements), vitamins, Seville oranges, grapefruit, or grapefruit juice at least 14 days before the administration of the first dose of the study drug. Prescription medications were not administered during the study. Volunteers had stopped over-the-counter medications no less than 2 days before the first administration of the study drug. Occasional use of acetaminophen or ibuprofen was allowed during the study for the treatment of pain. Volunteers could not consume alcohol from 72 h before the first dose of the study drug through the follow-up visit and were nonsmokers (subjects who stopped smoking at least 6 months before screening were considered nonsmokers).</p><p id="__p6" class="p p-last">The protocol and informed-consent form were approved in accordance with national procedures. All volunteers provided written informed consent before participating in the study. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.</p></div><div id="__sec4" class="sec"><p></p><h3 class="inline">Study design. </h3><p id="__p7" class="p p-first-last">This was a phase 1, open-label, single-center, nonrandomized study of telaprevir in combination with Caduet tablets containing 5 mg of amlodipine and 20 mg of atorvastatin (amlodipine-atorvastatin). Volunteers received the following treatment: a single dose of amlodipine-atorvastatin alone on day 1, followed by a washout period, telaprevir at a dose of 750 mg every 8 h (q8h) on days 11 through 26, with a single dose of amlodipine-atorvastatin on day 17. Outpatient visits occurred at the screening visit (between 3 and 28 days before the first administration of the study drug); on days 3, 4, 6, 8, 12 through 14, and 21 through 27; and at a final safety visit approximately 6 days after the last dose of the study drug. Volunteers were confined to the clinical research unit on days −1 to 2, 10 to 11, and 15 to 20.</p></div><div id="__sec5" class="sec"><p></p><h3 class="inline">Drugs administered. </h3><p id="__p8" class="p p-first">Telaprevir (375-mg tablets, Patheon, Mississauga, Ontario, Canada) was administered at 750 mg q8h orally in the fed state (30 min after the start of a meal or snack).</p><p id="__p9" class="p p-last">Amlodipine-atorvastatin (25-mg fixed dose combination tablets containing 5 mg amlodipine and 20 mg atorvastatin; Pfizer Incorporated, New York, NY) was administered orally as a single dose in accordance with the package insert 30 min after the start of breakfast (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B1" rid="B1" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">1</a>). During the study, compliance was assessed on an ongoing basis by counting returned dosage units and reviewing the volunteer logs. All volunteers were ≥90% compliant with the telaprevir dosing regimen, and all volunteers received their scheduled doses of amlodipine-atorvastatin (administered at the clinic).</p></div><div id="__sec6" class="sec"><p></p><h3 class="inline">Bioanalysis. </h3><p id="__p10" class="p p-first">Pharmacokinetic evaluations were based on the concentrations of amlodipine, atorvastatin, <em>ortho</em>-hydroxy atorvastatin, <em>para</em>-hydroxy atorvastatin, and telaprevir in plasma.</p><p id="__p11">Plasma amlodipine, atorvastatin, <em>ortho</em>-hydroxy atorvastatin, and <em>para</em>-hydroxy atorvastatin concentrations were determined predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 240 h after a single dose of amlodipine-atorvastatin on day 1 and predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 240 h after another single dose of amlodipine-atorvastatin on day 17. Neither amlodipine nor atorvastatin is an inhibitor of CYP3A, while telaprevir is a potent inhibitor of CYP3A. Thus, an effect of amlodipine and atorvastatin on telaprevir pharmacokinetics (PK) was not anticipated. Therefore, telaprevir PK were evaluated only on day 17 and compared to those found historically. Plasma telaprevir concentrations were determined at steady state predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 8 h after the morning dose of telaprevir on day 17.</p><p id="__p12">Analysis of all plasma samples was performed using validated liquid chromatography (normal phase) followed by tandem mass spectrometry (LC/MS/MS) methods at Covance Bioanalytical Services, LLC (Indianapolis, IN). Analytes and their internal standards (amlodipine-d4 maleic acid, atorvastatin-d5 sodium salt, <em>ortho</em>-hydroxy atorvastatin-phenyl-d5, <em>para</em>-hydroxy atorvastatin-phenyl-d5, and d11-telaprevir) were extracted from human plasma by liquid-liquid extraction. After evaporation under nitrogen, the residue of all analytes was reconstituted and analyzed using LC/MS/MS with selected ion monitoring in the positive-ion mode. Calibration curves were generated using weighted (1/<em>x</em><sup>2</sup>) linear least-square (LS) regression. The standard curve range was 0.0500 to 25.0 ng/ml for amlodipine (lower limit of quantitation [LLOQ], 0.0500 ng/ml), 0.250 to 100 ng/ml for atorvastatin (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for <em>para</em>-hydroxy atorvastatin (LLOQ, 0.250 ng/ml), 0.250 to 100 ng/ml for <em>ortho</em>-hydroxy atorvastatin (LLOQ, 0.250 ng/ml), and 2.00 to 1,000 ng/ml for telaprevir (LLOQ, 2.00 ng/ml).</p><p id="__p13" class="p p-last">The calibration curves and quality control data all met the prespecified acceptance criteria for each batch of samples assayed.</p></div><div id="__sec7" class="sec"><p></p><h3 class="inline">Pharmacokinetic analyses. </h3><p id="__p14" class="p p-first">Pharmacokinetic analyses were carried out using WinNonlin, version 5.0.1 (Pharsight Corporation, Mountain View, CA). Standard noncompartmental analyses for computation of the area under the concentration-time curve (AUC) were conducted. The maximum observed drug concentration in serum (<em>C</em><sub>max</sub>) and the time required to achieve the <em>C</em><sub>max</sub> (<em>t</em><sub>max</sub>) were determined directly from the data obtained. The AUC was computed using the linear trapezoidal rule between increasing concentrations and the log trapezoidal rule between decreasing concentrations. The AUC extrapolated to infinity (AUC<sub>0-∞</sub>) was computed as the cumulative AUC to the time (<em>t</em><sub>last</sub>) of the last quantifiable concentration (<em>C</em><sub>last</sub>), i.e., AUC<sub>last</sub>, plus the extrapolated AUC from <em>t</em><sub>last</sub> to infinity. AUC<sub><em>t</em>last-∞</sub> was estimated by dividing the <em>C</em><sub>last</sub> by the terminal elimination rate constant (λ<em>z</em>). The terminal half-life (<em>t</em><sub>1/2</sub>) was calculated as ln(2)/λ<em>z</em>, and oral clearance (CL/F, where F is oral bioavailability) was calculated by dividing the dose by the AUC<sub>0-∞</sub>.</p><p id="__p15">For all pharmacokinetic measurements and parameters, appropriate descriptive statistics were calculated, which included the arithmetic mean, the arithmetic standard deviation (SD), and the number of volunteers.</p><p id="__p16" class="p p-last">The drug-drug interaction was assessed by the linear mixed-effects modeling method using WinNonlin. The pharmacokinetic parameters (<em>C</em><sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>0-∞</sub>) of amlodipine and atorvastatin following a single dose of amlodipine-atorvastatin coadministered with telaprevir were compared to those measured following a single dose of amlodipine-atorvastatin alone. In the analysis, treatment effect (with or without telaprevir) was considered a fixed effect and subject was a random effect. Geometric LS means for each treatment and 90% confidence interval (CIs) for the geometric LS mean ratio (GLSMR) were reported. The absence of an interaction was to be concluded if the 90% CIs for the GLSMR fell within a range of 0.80 to 1.25 for each pharmacokinetic parameter (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B2" rid="B2" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">2</a>).</p></div><div id="__sec8" class="sec sec-last"><p></p><h3 class="inline">Safety assessments. </h3><p id="__p17" class="p p-first-last">Adverse events and concomitant medications were monitored throughout the study. Vital signs were assessed predose and at 4, 8, 10, and 24 h postdose; 12-lead electrocardiograms (ECGs) were assessed predose and at 8, 10, and 24 h postdose for amlodipine-atorvastatin when administered alone and when administered in combination with telaprevir. Clinical chemistry and hematology were assessed predose and on days 10, 15, and 20. Urinalysis was performed predose. All safety assessments were repeated at the safety follow-up visit conducted approximately 6 days following the last dose of the study medications.</p></div></div><div id="__sec9" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec9title" style="text-transform: uppercase;">RESULTS</h2><div id="__sec10" class="sec sec-first"><p></p><h3 class="inline">Demographics and disposition. </h3><p id="__p18" class="p p-first-last">Seventy-six percent of our healthy volunteers were Caucasian (<em>n</em> = 16), 19% were black or African American (<em>n</em> = 4), and 5% were Native American or Native Alaskan (<em>n</em> = 1), with a median age of 34 years (range, 21 to 53 years) and a median body mass index of 26.6 (range, 20.7 to 30.1). Twenty-one healthy volunteers were enrolled, and plasma samples from at least 19 volunteers were available following all dosing occasions and analyzed for amlodipine, atorvastatin, <em>ortho</em>-hydroxy atorvastatin, <em>para</em>-hydroxy atorvastatin, and telaprevir. Day 17 plasma samples from 2 volunteers were not available because they discontinued the study after providing blood samples for day 1 amlodipine-atorvastatin PK.</p></div><div id="__sec11" class="sec"><p></p><h3 class="inline">Effect of telaprevir on the PK of amlodipine. </h3><p id="__p19" class="p p-first">The mean plasma amlodipine concentration-time profile is shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Fig. 1</span></a>, and the pharmacokinetic parameter estimates from the noncompartmental analysis of amlodipine concentration data are shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. Based on the ratio of the LS means, the mean <em>C</em><sub>max</sub> and AUC<sub>0-∞</sub> of amlodipine were increased 1.27-fold and 2.79-fold, respectively, by the coadministration of telaprevir (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). The mean <em>t</em><sub>1/2</sub> of amlodipine increased from 41.3 h to 95.1 h, and the mean apparent clearance (CL/F) decreased from 38.0 liters/h to 12.3 liters/h.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><img src="./PMC3187007_files/zac9991002760001.gif" class="small-thumb" alt="Fig. 1." title="Fig. 1." src-large="/pmc/articles/PMC3187007/bin/zac9991002760001.jpg"></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Fig. 1.</a></div><!--caption a4--><div><span>Mean plasma concentration-time profile of amlodipine following oral administration with and without telaprevir. Error bars represent the standard error of the mean.</span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/table/T1/" target="table" rid-ob="ob-T1" rid-figpopup="T1" class="table img_link icnblk_img figpopup"><img alt="Table 1." title="Table 1." class="small-thumb" src="./PMC3187007_files/saved_resource" src-large="/pmc/articles/PMC3187007/table/T1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/table/T1/" target="table" rid-figpopup="T1" rid-ob="ob-T1">Table 1.</a></div><!--caption a4--><div><span>Effects of telaprevir on the PK of amlodipine, atorvastatin, and its metabolite <em>ortho</em>-hydroxy atorvastatin</span></div></div></div></div><div id="__sec12" class="sec"><p></p><h3 class="inline">Effect of telaprevir on the PK of atorvastatin and metabolites. </h3><p id="__p31" class="p p-first">The mean plasma atorvastatin concentration-time profile obtained is shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F2/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Fig. 2</span></a>, and the pharmacokinetic parameter estimates from the noncompartmental analysis of atorvastatin concentration data are shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. Based on the ratio of the LS means, the mean <em>C</em><sub>max</sub> and the AUC<sub>0-∞</sub> were markedly increased 10.6-fold and 7.88-fold, respectively, by the coadministration of telaprevir (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). The mean apparent clearance (CL/F) decreased from 685 liters/h to 83.8 liters/h. The mean (SD) <em>t</em><sub>1/2</sub> decreased from 9.44 (2.64) h to 6.75 (1.55) h with telaprevir coadministration; the difference in <em>t</em><sub>1/2</sub> was not statistically significant.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><img src="./PMC3187007_files/zac9991002760002.gif" class="small-thumb" alt="Fig. 2." title="Fig. 2." src-large="/pmc/articles/PMC3187007/bin/zac9991002760002.jpg"></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Fig. 2.</a></div><!--caption a4--><div><span>Mean plasma concentration-time profile of atorvastatin following oral administration with and without telaprevir. Error bars represent the standard error of the mean.</span></div></div></div><p id="__p33">The mean plasma concentration-time profiles of <em>ortho</em>-hydroxy atorvastatin following amlodipine-atorvastatin administration on day 1 and day 17 are shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F3/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Fig. 3</span></a>. Because a substantial number of sample concentrations for the 240-h sampling interval were close to the LLOQ (both day 1 and day 17), the concentration-versus-time profile of <em>ortho</em>-hydroxy atorvastatin is limited to 24 h postdose. As shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>, the variability of <em>C</em><sub>max</sub> and AUC<sub>0-∞</sub> on day 17 is quite large. The extrapolated component for AUC<sub>0-∞</sub> was over 25% in four volunteers on day 17; furthermore, the AUC calculation was performed using imputed data by replacing the first value below the quantitation limit (BQL) after <em>C</em><sub>last</sub> with half of the LLOQ. Thus, interpretation of these parameters should be done with caution and further interpretation would not be clinically meaningful with limited data. Thus, GLSMRs were not calculated for this analyte.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><img src="./PMC3187007_files/zac9991002760003.gif" class="small-thumb" alt="Fig. 3." title="Fig. 3." src-large="/pmc/articles/PMC3187007/bin/zac9991002760003.jpg"></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Fig. 3.</a></div><!--caption a4--><div><span>Mean plasma concentration-time profile of <em>ortho</em>-hydroxy-atorvastatin following oral administration with and without telaprevir. Error bars represent the standard error of the mean.</span></div></div></div><p id="__p35" class="p p-last">Most of the concentrations of <em>para</em>-hydroxy atorvastatin were below the LLOQ, especially on day 1. Only 2 volunteers showed detectable concentrations of <em>para</em>-hydroxy atorvastatin on day 1. The <em>C</em><sub>max</sub> of <em>para</em>-hydroxy atorvastatin in these 2 volunteers increased with telaprevir coadministration from 0.30 and 0.54 (mean of 0.42) ng/ml (day 1) to 1.92 and 2.89 (mean of 2.40) ng/ml (day 17).</p></div><div id="__sec13" class="sec"><p></p><h3 class="inline">Steady-state PK of telaprevir after coadministration with amlodipine and atorvastatin. </h3><p id="__p36" class="p p-first-last">Selected steady-state pharmacokinetic parameters were calculated for telaprevir on day 17 after coadministration with a single dose of amlodipine-atorvastatin. The mean (SD) <em>C</em><sub>max</sub> of telaprevir was 3,167 (778) ng/ml, and the mean (SD) AUC<sub>0-last</sub> of telaprevir was 20,471 (5,317) h · ng/ml. These values are similar to those observed historically (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B4" rid="B4" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">4</a>).</p></div><div id="__sec14" class="sec sec-last"><p></p><h3 class="inline">Safety. </h3><p id="__p37" class="p p-first">There were no serious, life-threatening, or severe adverse events. One volunteer left the study due to an adverse event (herpes zoster) during the telaprevir-alone period. This was considered possibly related to treatment, was mild in severity, and resolved without intervention. With only one exception, all adverse events were considered to be of mild severity. The exception was moderate diarrhea in one volunteer during the telaprevir-amlodipine-atorvastatin combination period.</p><p id="__p38">Thirteen (62%) volunteers reported an adverse event, and 10 (48%) volunteers reported an adverse event that was considered drug related by the investigator. The most frequent adverse events that were considered to be related to the treatment occurred in the nervous system or the gastrointestinal system. The most frequent adverse events (considered either related or unrelated to a study drug by the investigator) included headache (occurred in 5 volunteers [24%] during the amlodipine-atorvastatin-alone period, in 2 volunteers [10%] during the telaprevir-alone period, and in 1 volunteer [5%] during the telaprevir-amlodipine-atorvastatin combination period); dizziness (occurred in 2 volunteers [10%] during the telaprevir-alone period, and in 3 volunteers [15%] during the telaprevir-amlodipine-atorvastatin combination period); diarrhea (occurred in 1 volunteer [5%] during each of the 3 periods); nausea (occurred in 1 volunteer [5%] during the telaprevir-alone period and in 2 volunteers [11%] during the telaprevir-amlodipine-atorvastatin combination period). Rash has been previously reported with telaprevir administration (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B3" rid="B3" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">3</a>). A mild papular rash was reported in a single volunteer (4.8%) on day 24 during the period of coadministration of amlodipine-atorvastatin and telaprevir; the rash resolved without treatment or a change in study drug dosing.</p><p id="__p39" class="p p-last">There were no clinically significant changes from the baseline in clinical laboratory values, vital signs, ECG parameters, or physical examination. A creatine kinase level elevation can be associated with increased statin levels (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B1" rid="B1" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">1</a>). However, there were no clinically significant changes in creatine kinase reported as adverse events in any volunteers.</p></div></div><div id="__sec15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec15title" style="text-transform: uppercase;">DISCUSSION</h2><p id="__p40" class="p p-first">Potential drug-drug interactions of telaprevir with amlodipine and atorvastatin were investigated in healthy volunteers by comparing the PK of these drugs with and without the coadministration of telaprevir. A formulation containing a combination of amlodipine and atorvastatin (Caduet) was used in this study for dosing convenience. No significant interaction between amlodipine and atorvastatin was expected.</p><p id="__p41">A clinical drug-drug interaction study of telaprevir and midazolam showed that telaprevir increased the AUC of oral midazolam almost 9-fold (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B4" rid="B4" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">4</a>), indicating that telaprevir is a potent inhibitor of CYP3A4. Amlodipine is a dihydropyridine calcium antagonist drug and has been reported as a substrate and mild inhibitor of CYP3A from both <em>in vitro</em> liver microsomal incubation and clinical studies (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921854" role="button" aria-expanded="false" aria-haspopup="true">9</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921857" role="button" aria-expanded="false" aria-haspopup="true">13</a>). Atorvastatin, one of the most commonly prescribed HMG-CoA reductase inhibitors, is also a substrate of CYP3A (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921849" role="button" aria-expanded="false" aria-haspopup="true">6</a>). Adverse events such as rhabdomyolysis and myopathy have been reported with statins, and most of the statin drug interactions are attributed to metabolism catalyzed by cytochrome P450 (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921852" role="button" aria-expanded="false" aria-haspopup="true">22</a>). Thus, clinically significant changes in the PK of amlodipine and atorvastatin, administered as Caduet, were anticipated with the coadministration of telaprevir.</p><p id="__p42">Results from the present study indicate that telaprevir significantly inhibited the metabolism of both amlodipine and atorvastatin. The bioavailability of amlodipine has been reported to be ∼60% (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921861" role="button" aria-expanded="false" aria-haspopup="true">14</a>). It is extensively metabolized by the liver and is very slowly cleared from the body (elimination <em>t</em><sub>1/2</sub>, ∼45 h). Its volume of distribution is known to be large (∼21 liters/kg), with a high level of binding to the plasma albumin (∼98%) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921848" role="button" aria-expanded="false" aria-haspopup="true">15</a>). When amlodipine was coadministered with telaprevir, its AUC<sub>0-∞</sub> increased 2.79-fold and its <em>C</em><sub>max</sub> increased 1.27-fold. The mean (SD) <em>t</em><sub>1/2</sub> increased from 41.3 (8.2) h to 95.1 (23.6) h, and the mean (SD) apparent clearance (CL/F) decreased from 38.0 (11.8) liters/h to 12.3 (2.97) liters/h. The increased <em>t</em><sub>1/2</sub> associated with the clearance decrease signifies the inhibitory effect of telaprevir on the metabolism of amlodipine. An effect of a similar magnitude on amlodipine has been observed in other studies with antiviral agents that are CYP3A inhibitors. For example, combined dosing of indinavir and ritonavir increased the median amlodipine AUC<sub>0-24</sub> by 90% (<em>n</em> = 18) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921855" role="button" aria-expanded="false" aria-haspopup="true">5</a>).</p><p id="__p43">The effect of telaprevir on atorvastatin disposition was more pronounced. Atorvastatin is given in the acid form, and its <em>C</em><sub>max</sub> is achieved quickly (∼1 to 2 h postdose) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921864" role="button" aria-expanded="false" aria-haspopup="true">10</a>). Atorvastatin acid undergoes extensive first-pass metabolism in the gut and the liver, and therefore its oral bioavailability is only ∼14%. Its volume of distribution has been reported to be ∼380 liters, with a high degree of plasma protein binding, mainly to albumin (98%) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921863" role="button" aria-expanded="false" aria-haspopup="true">22</a>).</p><p id="__p44">Upon the coadministration of telaprevir with a single dose of amlodipine-atorvastatin, the atorvastatin AUC<sub>0-∞</sub> increased 7.88-fold and the atorvastatin <em>C</em><sub>max</sub> increased 10.6-fold. These results suggest that the primary effect of telaprevir on atorvastatin is to increase its bioavailability (F) by decreasing its first-pass metabolism by CYP3A and/or increasing its net absorption by inhibiting P-glycoprotein-mediated efflux back to the gut. The effect of telaprevir on the hepatic metabolism of atorvastatin does not appear to be significant in its overall disposition. An effect of a similar magnitude on atorvastatin has been observed in studies using some other CYP3A inhibitors. For example, the AUC and <em>C</em><sub>max</sub> of atorvastatin were increased about 9-fold when it was coadministered with tipranavir-ritonavir at steady state (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921858" role="button" aria-expanded="false" aria-haspopup="true">16</a>).</p><p id="__p45">With coadministration of telaprevir, the mean (SD) apparent clearance decreased from 685 (272) liters/h to 83.8 (32.7) liters/h and the apparent volume of distribution decreased from 8,984 (3,431) liters to 838 (405) liters. The mean (SD) terminal <em>t</em><sub>1/2</sub> decreased from 9.44 (2.64) h to 6.75 (1.55) h with the coadministration of telaprevir, although this difference was not statistically significant. Inhibition of atorvastatin metabolism would be expected to increase the atorvastatin <em>t</em><sub>1/2</sub>. This unexpected result may be caused by the inhibition of transporters involved in the hepatic uptake of atorvastatin, such as organic anion-transporting polypeptide 1B1 (OATP1B1), which could reduce the volume of distribution of atorvastatin to an extent similar to or greater than the observed decrease in systemic clearance. Such a mechanism has been hypothesized for the effect of cyclosporine (an inhibitor of OATP1B1) on rosuvastatin, a statin which is also a substrate of OATP1B1 and whose <em>t</em><sub>1/2</sub> was decreased by half upon the coadministration of cyclosporine (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921862" role="button" aria-expanded="false" aria-haspopup="true">19</a>). Other statins that are substrates of OATP1B1, such as cerivastatin, fluvastatin, and atorvastatin, showed unaltered <em>t</em><sub>1/2</sub>s, while severalfold AUC and <em>C</em><sub>max</sub> increases resulted when the drugs were coadministered with cyclosporine (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921845" role="button" aria-expanded="false" aria-haspopup="true">18</a>). However, at this time, the effect of telaprevir on OATP1B1 is unknown.</p><p id="__p46">The mean AUC<sub>0-∞</sub> for <em>ortho</em>-hydroxy atorvastatin decreased by approximately 70% after telaprevir coadministration; however, most concentrations of <em>para</em>-hydroxy atorvastatin were below the LLOQ, making noncompartmental analysis for this metabolite not feasible. In the 2 volunteers in whom <em>para</em>-hydroxy atorvastatin was measurable before (day 1) and after (day 17) the coadministration of telaprevir, the concentrations of this metabolite increased about 6-fold. On day 17, but not day 1, several other volunteers had measurable concentrations of <em>para</em>-hydroxy atorvastatin. While these results were not anticipated, it has been reported that <em>para</em>-hydroxy atorvastatin, but not <em>ortho</em>-hydroxy atorvastatin, is also formed by CYP2C8 in addition to CYP3A (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921847" role="button" aria-expanded="false" aria-haspopup="true">7</a>). Therefore, in the presence of greater systemic exposure of atorvastatin during the coadministration of telaprevir, it is plausible that more <em>para</em>-hydroxy atorvastatin is formed via CYP2C8 and its concentration in plasma is increased.</p><p id="__p47">The PK of telaprevir were evaluated after coadministration at steady state with a single dose of amlodipine-atorvastatin. The <em>C</em><sub>max</sub> and AUC<sub>last</sub> were similar to the steady-state estimates obtained in other studies (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B21" rid="B21" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">21</a>). This suggests that adequate telaprevir exposure was achieved in this study and a clinically significant effect of amlodipine or atorvastatin on telaprevir is unlikely.</p><p id="__p48">The coadministration of multiple doses of telaprevir with one dose of amlodipine and atorvastatin administered in 2 periods was well tolerated. There were no serious, life-threatening, or severe adverse events, no volunteers discontinued due to an adverse event, and most of the adverse events reported were mild. The frequently reported adverse events included, headache, dizziness, diarrhea, and nausea, all of which have been reported in other clinical trials after the administration of telaprevir alone (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921860" role="button" aria-expanded="false" aria-haspopup="true">8</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B17" rid="B17" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">17</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_233921853" role="button" aria-expanded="false" aria-haspopup="true">23</a>). The low frequency and/or lack of adverse events commonly associated with amlodipine and atorvastatin may be attributed to the single-dose regimen of these drugs used in this study.</p><p id="__p49" class="p p-last">In summary, the results of this study suggest that telaprevir significantly increased exposure to amlodipine and atorvastatin (<em>C</em><sub>max</sub> and AUC<sub>0-∞</sub>). Atorvastatin coadministration with telaprevir is contraindicated. When amlodipine is coadministered with telaprevir, caution should be used and an amlodipine dose reduction should be considered. Clinical monitoring is recommended. Please check the INCIVEK package insert for full information and/or updates (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B3" rid="B3" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">3</a>).</p></div><div id="__ackid738286" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ackid738286title" style="text-transform: uppercase;">ACKNOWLEDGMENTS</h2><div class="sec"><p id="__p51">We acknowledge the contribution of J. H. Frank Farmer, Jr., of the Covance Clinical Research Unit (Daytona Beach, FL), who was contracted to serve as an investigator in this study. Additionally, we acknowledge the assistance of the following Vertex Pharmaceuticals Incorporated employees and stockholders: Mahlet Woldermarian for study coordination and support, Megan Melch and Lakshmi Viswanathan for assistance in the preparation of the manuscript, Kristin Stephan for editorial coordination and support, and Jonathan Kirk for graphic design support.</p><p id="__p52">This study was supported by Vertex Pharmaceuticals Incorporated and Tibotec BVBA.</p><p id="__p53">We were all employed by either Vertex (V.G., J.E.L., K.A., F.S., and R.K.) or Tibotec (R.V.) at the time of this study and own stock in these companies.</p><p id="__p54">J.E.L. is currently employed by the U.S. Food and Drug Administration. Her contribution to the manuscript was based on her prior employment, and the content of the work does not necessarily reflect any position of the U.S. Food and Drug Administration.</p></div></div><div id="__fn-groupid738272" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__fn-groupid738272title" style="text-transform: uppercase;">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN1"><sup>▿</sup>Published ahead of print on 8 August 2011.</p></div></div><div id="__ref-listid412305" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-21"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-22">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid412305title" style="text-transform: uppercase;">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1">1. <span class="mixed-citation">
 2011.  <span class="ref-journal">Caduet package insert</span>. Pfizer Incorporated, New York, NY:  <a href="http://labeling.pfizer.com/ShowLabeling.aspx?id=531" ref="reftype=extlink&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://labeling.pfizer.com/ShowLabeling.aspx?id=531</a></span></div><div class="ref-cit-blk half_rhythm" id="B2">2. <span class="mixed-citation">
 2006.  <span class="ref-journal">FDA draft guidance on drug interaction studies: study design, data analysis, and implications for dosing and labeling</span>. Food and Drug Administration, Washington, DC</span></div><div class="ref-cit-blk half_rhythm" id="B3">3. <span class="mixed-citation">
 2011.  <span class="ref-journal">INCIVEK package insert</span>. Vertex Pharmaceuticals Incorporated, Cambridge, MA:  <a href="http://pi.vrtx.com/files/uspi_telaprevir.pdf" ref="reftype=extlink&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://pi.vrtx.com/files/uspi_telaprevir.pdf</a></span></div><div class="ref-cit-blk half_rhythm" id="B4">4. <span class="mixed-citation">
Garg V., Chandorkar G., Smith F., Alves K., van Heeswijk R. 2011.  <span class="ref-title">The effect of telaprevir on the pharmacokinetics of midazolam and digoxin</span>. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, 22–23 June 2011, Boston, MA <a href="http://regist2.virology-education.com/2011/6HEPPK/docs/08_Garg.pdf" ref="reftype=extlink&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://regist2.virology-education.com/2011/6HEPPK/docs/08_Garg.pdf</a></span></div><div class="ref-cit-blk half_rhythm" id="B5">5. <span class="mixed-citation">
Glesby M. J., et al.  2005.  <span class="ref-title">Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers</span>. <span class="ref-journal">Clin. Pharmacol. Ther</span>. <span class="ref-vol">78</span>:143–153  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16084849" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6">6. <span class="mixed-citation">
Hermann M., et al.  2006.  <span class="ref-title">Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in volunteers with atorvastatin-induced myopathy</span>. <span class="ref-journal">Clin. Pharmacol. Ther</span>. <span class="ref-vol">79</span>:532–539  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16765141" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7">7. <span class="mixed-citation">
Jacobsen W., et al.  2000.  <span class="ref-title">Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin</span>. <span class="ref-journal">Drug Metab. Dispos</span>. <span class="ref-vol">28</span>:1369–1378  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11038166" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8">8. <span class="mixed-citation">
Jacobson I. M., et al.  2011.  <span class="ref-title">Telaprevir for previously untreated chronic hepatitis C virus infection</span>. <span class="ref-journal">N. Engl. J. Med</span>. <span class="ref-vol">364</span>:2405–2416  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21696307" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9">9. <span class="mixed-citation">
Josefsson M., Zackrisson A. L., Ahlner J. 1996.  <span class="ref-title">Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers</span>. <span class="ref-journal">Eur. J. Clin. Pharmacol</span>. <span class="ref-vol">51</span>:189–193  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8911887" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10">10. <span class="mixed-citation">
Lennernäs H. 2003.  <span class="ref-title">Clinical pharmacokinetics of atorvastatin</span>. <span class="ref-journal">Clin. Pharmacokinet</span>. <span class="ref-vol">42</span>:1141–1160  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14531725" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11">11. <span class="mixed-citation">
Lin C., Kwong A. D., Perni R. B. 2006.  <span class="ref-title">Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease</span>. <span class="ref-journal">Infect. Disord. Drug Targets</span> <span class="ref-vol">6</span>:3–16  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16787300" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12">12. <span class="mixed-citation">
Lins R. L., et al.  2003.  <span class="ref-title">Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients</span>. <span class="ref-journal">Nephrol. Dial. Transplant</span>. <span class="ref-vol">18</span>:967–976  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12686673" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13">13. <span class="mixed-citation">
McGregor D. O., Bailey R. R., Robson R. A. 1997.  <span class="ref-title">Amlodipine has a minor effect on cyclosporine metabolism</span>. <span class="ref-journal">Clin. Nephrol</span>. <span class="ref-vol">48</span>:336.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9403222" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14">14. <span class="mixed-citation">
Meredith P. A., Elliott H. L. 1992.  <span class="ref-title">Clinical pharmacokinetics of amlodipine</span>. <span class="ref-journal">Clin. Pharmacokinet</span>. <span class="ref-vol">22</span>:22–31  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1532771" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15">15. <span class="mixed-citation">
Murdoch D., Heel R. C. 1991.  <span class="ref-title">Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease</span>. <span class="ref-journal">Drugs</span> <span class="ref-vol">41</span>:478–505  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1711448" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16">16. <span class="mixed-citation">
Pham P. A., et al.  2009.  <span class="ref-title">Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers</span>. <span class="ref-journal">Antimicrob. Agents Chemother</span>. <span class="ref-vol">53</span>:4385–4392 <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764168/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19667285" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17">17. <span class="mixed-citation">
Sherman K. E., et al.  2010.  <span class="ref-title">Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV volunteers who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study</span>. 61st Annu. Meet. AASLD, Boston, Ma, 30 October-3 November 2010 <a href="http://www.natap.org/2010/AASLD/AASLD_21.htm" ref="reftype=extlink&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.natap.org/2010/AASLD/AASLD_21.htm</a></span></div><div class="ref-cit-blk half_rhythm" id="B18">18. <span class="mixed-citation">
Shitara Y. 2011.  <span class="ref-title">Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions</span>. <span class="ref-journal">Drug Metab. Pharmacokinet</span>. <span class="ref-vol">26</span>:220–227  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21297316" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19">19. <span class="mixed-citation">
Simonson S. G., et al.  2004.  <span class="ref-title">Rosuvastatin pharmacokinetics in heart transplant recipient administered and antirejection regimen including cyclosporine</span>. <span class="ref-journal">Clin. Pharmacol. Ther</span>. <span class="ref-vol">76</span>:167–177  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20">20. <span class="mixed-citation">
Stopher D. A., Beresford A. P., Macrae P. V., Humphrey M. J. 1988.  <span class="ref-title">The metabolism and pharmacokinetics of amlodipine in humans and animals</span>. <span class="ref-journal">J. Cardiovasc. Pharmacol</span>. <span class="ref-vol">12</span>(<span class="ref-iss">Suppl. 7</span>):S55–S59  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/2467130" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21">21. <span class="mixed-citation">
van Heeswijk R., et al.  2008.  <span class="ref-title">The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir, abstr. A-966</span>. 48th ICAAC, Washington, DC, 25–28 October 2008</span></div><div class="ref-cit-blk half_rhythm" id="B22">22. <span class="mixed-citation">
Williams D. 2002.  <span class="ref-title">Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors</span>. <span class="ref-journal">Clin. Pharmacokinet</span>. <span class="ref-vol">41</span>:343–370  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12036392" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23">23. <span class="mixed-citation">
Zeuzem S., et al.  2011.  <span class="ref-title">Telaprevir for retreatment of HCV infection</span>. <span class="ref-journal">N. Engl. J. Med</span>. <span class="ref-vol">364</span>:2417–2428  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21696308" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#__abstractid419012title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#__sec1title">INTRODUCTION</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#__sec2title">MATERIALS AND METHODS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#__sec9title">RESULTS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#__sec15title">DISCUSSION</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#__ackid738286title">ACKNOWLEDGMENTS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#__fn-groupid738272title">Footnotes</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#__ref-listid412305title">REFERENCES</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">Antimicrobial Agents and Chemotherapy</span> are provided here courtesy of <strong>American Society for Microbiology (ASM)</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/?report=reader"><img src="./PMC3187007_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/pdf/zac4569.pdf">PDF (183K)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" data-citationid="PMC3187007" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3187007%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3187007_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3187007%2F&amp;text=Effect%20of%20the%20Hepatitis%20C%20Virus%20Protease%20Inhibitor%20Telaprevir%20on%20the%20Pharmacokinetics%20of%20Amlodipine%20and%20Atorvastatin" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3187007_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3187007%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3187007_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="21825288" data-aiid="3187007" data-aid="3187007" data-iid="200756" data-domainid="82" data-domain="aac" data-accid="PMC3187007" data-md5="77e92510101dd1a9bb50d1e14b0a7633">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-25" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-25" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="3187007"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-27" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-27" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/16920898" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet.</a><span class="source">[J Clin Pharmacol. 2006]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-29" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chung M, Calcagni A, Glue P, Bramson C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Pharmacol. 2006 Sep; 46(9):1030-7. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/23369879" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS.</a><span class="source">[J Chromatogr B Analyt Technol ...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-31" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Yacoub M, Awwad AA, Alawi M, Arafat T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Feb 15; 917-918:36-47. Epub 2013 Jan 9.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/23529734" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.</a><span class="source">[Antimicrob Agents Chemother. 2...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-33" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antimicrob Agents Chemother. 2013 Jun; 57(6):2582-8. Epub 2013 Mar 25.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/20108992" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.</a><span class="source">[Drugs. 2010]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-35" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Curran MP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2010; 70(2):191-213. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/22954756" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Telaprevir: pharmacokinetics and drug interactions.</a><span class="source">[Antivir Ther. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-37" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antivir Ther. 2012; 17(7):1211-21. Epub 2012 Sep 7.</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=21825288&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=21825288&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-39" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-39" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784678/" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Drug-drug interactions and Idiosyncratic Hepatotoxicity in the Liver Transplant setting</a><span class="source">[Journal of hepatology. 2013]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-41" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tischer S, Fontana RJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Journal of hepatology. 2013 Nov 23; 60(4)872-884</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507099/" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes</a><span class="source">[World Journal of Gastroenterol...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-43" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Simon TG, Butt AA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">World Journal of Gastroenterology : WJG. 2015 Jul 21; 21(27)8293-8303</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135986/" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides</a><span class="source">[Antimicrobial Agents and Chemo...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, Kobayashi K, Chiba K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antimicrobial Agents and Chemotherapy. 2014 Aug; 58(8)4555-4564</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078386/" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Statin efficacy in the treatment of hepatitis C genotype I</a><span class="source">[Journal of Research in Medical...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-47" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shavakhi A, Minakari M, Bighamian A, Sadeghian S, Shavakhi S, Khamisi N, Khodadustan M, Talebi M, Ataei B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences. 2014 Mar; 19(Suppl 1)S1-S4</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691435/" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective</a><span class="source">[The AAPS Journal. 2013]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-49" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Prueksaritanont T, Chu X, Gibson C, Cui D, Yee KL, Ballard J, Cabalu T, Hochman J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">The AAPS Journal. 2013 Mar 30; 15(3)629-645</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/citedby/" ref="reftype=relart&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-51" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-51" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=books&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_books_refs&amp;IdsFromResult=3187007" ref="reftype=Cited%20in%20Books&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Books&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Cited in Books</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-53" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Cited in Books<div class="brieflinkpopdesc">PubMed Central articles cited in books</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=3187007" ref="reftype=Compound&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-55" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=3187007" ref="reftype=MedGen&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-57" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/21825288/" ref="reftype=PubMed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-59" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=3187007" ref="reftype=Substance&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-61" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=taxonomy&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_taxonomy&amp;IdsFromResult=3187007" ref="reftype=Taxonomy&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Taxonomy</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-63" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Taxonomy<div class="brieflinkpopdesc">Related taxonomy entry</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-65" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-65" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c289ef2911de5257db42d">Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokin...</a><div class="ralinkpop offscreen_noflow">Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin<div class="brieflinkpopdesc">Antimicrobial Agents and Chemotherapy. 2011 Oct; 55(10)4569</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c289a7fd84438f0ea2510">PMC3187007 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c28897fd84438f0ea2202">Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers</a><div class="ralinkpop offscreen_noflow">Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2011 Aug; 72(2)321</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c28867fd84438f0ea21a8">PMC3162661 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2876f2911de5257dada7">Effect of Single-dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Vo...</a><div class="ralinkpop offscreen_noflow">Effect of Single-dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2010 Oct; 88(4)540</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p2" name="crb--__p2" rid="__p2" style="position: absolute; visibility: visible; width: 370px; top: 853px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-67"><ul>
<li class="two_line" reference_id="B11">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16787300/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.</a><span class="one_line_source">[Infect Disord Drug Targets.  2006]</span><div class="alt-note">
<div class="authors">Lin C, Kwong AD, Perni RB</div>
<div class="citation">Infect Disord Drug Targets. 2006 Mar; 6(1):3-16.</div>
</div>
</li>
<li class="two_line" reference_id="B8" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/21696307/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Telaprevir for previously untreated chronic hepatitis C virus infection.</a><span class="one_line_source">[N Engl J Med.  2011]</span><div class="alt-note">
<div class="authors">Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team</div>
<div class="citation">N Engl J Med. 2011 Jun 23; 364(25):2405-16.</div>
</div>
</li>
<li class="two_line" reference_id="B23" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/21696308/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Telaprevir for retreatment of HCV infection.</a><span class="one_line_source">[N Engl J Med.  2011]</span><div class="alt-note">
<div class="authors">Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team</div>
<div class="citation">N Engl J Med. 2011 Jun 23; 364(25):2417-28.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p3" name="crb--__p3" rid="__p3" style="position: absolute; visibility: visible; width: 370px; top: 969px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-68"><ul>
<li class="two_line" reference_id="B12">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12686673/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.</a><span class="one_line_source">[Nephrol Dial Transplant.  2003]</span><div class="alt-note">
<div class="authors">Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH</div>
<div class="citation">Nephrol Dial Transplant. 2003 May; 18(5):967-76.</div>
</div>
</li>
<li class="two_line" reference_id="B6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16765141/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.</a><span class="one_line_source">[Clin Pharmacol Ther.  2006]</span><div class="alt-note">
<div class="authors">Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K</div>
<div class="citation">Clin Pharmacol Ther. 2006 Jun; 79(6):532-9.</div>
</div>
</li>
<li class="two_line" reference_id="B20">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/2467130/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The metabolism and pharmacokinetics of amlodipine in humans and animals.</a><span class="one_line_source">[J Cardiovasc Pharmacol.  1988]</span><div class="alt-note">
<div class="authors">Stopher DA, Beresford AP, Macrae PV, Humphrey MJ</div>
<div class="citation">J Cardiovasc Pharmacol. 1988; 12 Suppl 7():S55-9.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p41" name="crb--__p41" rid="__p41" style="position: absolute; visibility: visible; width: 370px; top: 5346px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-69"><ul>
<li class="two_line" reference_id="B9">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8911887/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.</a><span class="one_line_source">[Eur J Clin Pharmacol.  1996]</span><div class="alt-note">
<div class="authors">Josefsson M, Zackrisson AL, Ahlner J</div>
<div class="citation">Eur J Clin Pharmacol. 1996; 51(2):189-93.</div>
</div>
</li>
<li class="two_line" reference_id="B13">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9403222/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Amlodipine has a minor effect on cyclosporine metabolism.</a><span class="one_line_source">[Clin Nephrol.  1997]</span><div class="alt-note">
<div class="authors">McGregor DO, Bailey RR, Robson RA</div>
<div class="citation">Clin Nephrol. 1997 Nov; 48(5):336.</div>
</div>
</li>
<li class="two_line" reference_id="B6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16765141/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.</a><span class="one_line_source">[Clin Pharmacol Ther.  2006]</span><div class="alt-note">
<div class="authors">Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K</div>
<div class="citation">Clin Pharmacol Ther. 2006 Jun; 79(6):532-9.</div>
</div>
</li>
<li class="two_line" reference_id="B22">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12036392/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.</a><span class="one_line_source">[Clin Pharmacokinet.  2002]</span><div class="alt-note">
<div class="authors">Williams D, Feely J</div>
<div class="citation">Clin Pharmacokinet. 2002; 41(5):343-70.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p42" name="crb--__p42" rid="__p42" style="position: absolute; visibility: visible; width: 370px; top: 5546px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-70"><ul>
<li class="two_line" reference_id="B14">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/1532771/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Clinical pharmacokinetics of amlodipine.</a><span class="one_line_source">[Clin Pharmacokinet.  1992]</span><div class="alt-note">
<div class="authors">Meredith PA, Elliott HL</div>
<div class="citation">Clin Pharmacokinet. 1992 Jan; 22(1):22-31.</div>
</div>
</li>
<li class="two_line" reference_id="B15">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/1711448/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.</a><span class="one_line_source">[Drugs.  1991]</span><div class="alt-note">
<div class="authors">Murdoch D, Heel RC</div>
<div class="citation">Drugs. 1991 Mar; 41(3):478-505.</div>
</div>
</li>
<li class="two_line" reference_id="B5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16084849/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.</a><span class="one_line_source">[Clin Pharmacol Ther.  2005]</span><div class="alt-note">
<div class="authors">Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, Grosskopf N, Zolopa AR, Gerber JG, Adult AIDS Clinical Trials Group A5159 Protocol Team</div>
<div class="citation">Clin Pharmacol Ther. 2005 Aug; 78(2):143-53.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p43" name="crb--__p43" rid="__p43" style="position: absolute; visibility: visible; width: 370px; top: 5798px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-71"><ul>
<li class="two_line" reference_id="B10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14531725/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Clinical pharmacokinetics of atorvastatin.</a><span class="one_line_source">[Clin Pharmacokinet.  2003]</span><div class="alt-note">
<div class="authors">Lennernäs H</div>
<div class="citation">Clin Pharmacokinet. 2003; 42(13):1141-60.</div>
</div>
</li>
<li class="two_line" reference_id="B22">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12036392/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.</a><span class="one_line_source">[Clin Pharmacokinet.  2002]</span><div class="alt-note">
<div class="authors">Williams D, Feely J</div>
<div class="citation">Clin Pharmacokinet. 2002; 41(5):343-70.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p44" name="crb--__p44" rid="__p44" style="position: absolute; visibility: visible; width: 370px; top: 5916px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-72"><ul><li class="two_line" reference_id="B16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19667285/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.</a><span class="one_line_source">[Antimicrob Agents Chemother.  2009]</span><div class="alt-note">
<div class="authors">Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, Piliero PJ, Barditch-Crovo P, Fuchs E, Flexner C, Cameron DW</div>
<div class="citation">Antimicrob Agents Chemother. 2009 Oct; 53(10):4385-92.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p45" name="crb--__p45" rid="__p45" style="position: absolute; visibility: visible; width: 370px; top: 6100px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-73"><ul>
<li class="two_line" reference_id="B19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.</a><span class="one_line_source">[Clin Pharmacol Ther.  2004]</span><div class="alt-note">
<div class="authors">Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW</div>
<div class="citation">Clin Pharmacol Ther. 2004 Aug; 76(2):167-77.</div>
</div>
</li>
<li class="two_line" reference_id="B18">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/21297316/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.</a><span class="one_line_source">[Drug Metab Pharmacokinet.  2011]</span><div class="alt-note">
<div class="authors">Shitara Y</div>
<div class="citation">Drug Metab Pharmacokinet. 2011 Jun; 26(3):220-7.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p46" name="crb--__p46" rid="__p46" style="position: absolute; visibility: visible; width: 370px; top: 6413px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-74"><ul><li class="two_line" reference_id="B7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11038166/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.</a><span class="one_line_source">[Drug Metab Dispos.  2000]</span><div class="alt-note">
<div class="authors">Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U</div>
<div class="citation">Drug Metab Dispos. 2000 Nov; 28(11):1369-78.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p48" name="crb--__p48" rid="__p48" style="position: absolute; visibility: visible; width: 370px; top: 6733px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-75"><ul>
<li class="two_line" reference_id="B8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/21696307/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Telaprevir for previously untreated chronic hepatitis C virus infection.</a><span class="one_line_source">[N Engl J Med.  2011]</span><div class="alt-note">
<div class="authors">Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team</div>
<div class="citation">N Engl J Med. 2011 Jun 23; 364(25):2405-16.</div>
</div>
</li>
<li class="two_line" reference_id="B23">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/21696308/" ref="reftype=pubmed&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Telaprevir for retreatment of HCV infection.</a><span class="one_line_source">[N Engl J Med.  2011]</span><div class="alt-note">
<div class="authors">Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team</div>
<div class="citation">N Engl J Med. 2011 Jun 23; 364(25):2417-28.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC3187007_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-B11" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.<div class="authors">Lin C, Kwong AD, Perni RB</div><div class="citation">Infect Disord Drug Targets. 2006 Mar; 6(1):3-16.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16787300/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B11">Ref list</a>]</p></div><div id="body-link-popper-B8" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Telaprevir for previously untreated chronic hepatitis C virus infection.<div class="authors">Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team</div><div class="citation">N Engl J Med. 2011 Jun 23; 364(25):2405-16.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21696307/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B8">Ref list</a>]</p></div><div id="body-link-popper-B17" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">17. <span class="mixed-citation">
Sherman K. E., et al.  2010.  <span class="ref-title">Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV volunteers who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study</span>. 61st Annu. Meet. AASLD, Boston, Ma, 30 October-3 November 2010 <a href="http://www.natap.org/2010/AASLD/AASLD_21.htm" ref="reftype=extlink&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.natap.org/2010/AASLD/AASLD_21.htm</a></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B17">Ref list</a>]</div><div id="body-link-popper-B23" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Telaprevir for retreatment of HCV infection.<div class="authors">Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team</div><div class="citation">N Engl J Med. 2011 Jun 23; 364(25):2417-28.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21696308/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B23">Ref list</a>]</p></div><div id="body-link-popper-B3" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">3. <span class="mixed-citation">
 2011.  <span class="ref-journal">INCIVEK package insert</span>. Vertex Pharmaceuticals Incorporated, Cambridge, MA:  <a href="http://pi.vrtx.com/files/uspi_telaprevir.pdf" ref="reftype=extlink&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://pi.vrtx.com/files/uspi_telaprevir.pdf</a></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B3">Ref list</a>]</div><div id="body-link-popper-B1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">1. <span class="mixed-citation">
 2011.  <span class="ref-journal">Caduet package insert</span>. Pfizer Incorporated, New York, NY:  <a href="http://labeling.pfizer.com/ShowLabeling.aspx?id=531" ref="reftype=extlink&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://labeling.pfizer.com/ShowLabeling.aspx?id=531</a></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B1">Ref list</a>]</div><div id="body-link-popper-B12" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.<div class="authors">Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH</div><div class="citation">Nephrol Dial Transplant. 2003 May; 18(5):967-76.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12686673/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B12">Ref list</a>]</p></div><div id="body-link-popper-B6" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.<div class="authors">Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K</div><div class="citation">Clin Pharmacol Ther. 2006 Jun; 79(6):532-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16765141/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B6">Ref list</a>]</p></div><div id="body-link-popper-B20" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The metabolism and pharmacokinetics of amlodipine in humans and animals.<div class="authors">Stopher DA, Beresford AP, Macrae PV, Humphrey MJ</div><div class="citation">J Cardiovasc Pharmacol. 1988; 12 Suppl 7():S55-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/2467130/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B20">Ref list</a>]</p></div><div id="body-link-popper-B2" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">2. <span class="mixed-citation">
 2006.  <span class="ref-journal">FDA draft guidance on drug interaction studies: study design, data analysis, and implications for dosing and labeling</span>. Food and Drug Administration, Washington, DC</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B2">Ref list</a>]</div><div id="body-link-popper-B4" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">4. <span class="mixed-citation">
Garg V., Chandorkar G., Smith F., Alves K., van Heeswijk R. 2011.  <span class="ref-title">The effect of telaprevir on the pharmacokinetics of midazolam and digoxin</span>. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, 22–23 June 2011, Boston, MA <a href="http://regist2.virology-education.com/2011/6HEPPK/docs/08_Garg.pdf" ref="reftype=extlink&amp;article-id=3187007&amp;issue-id=200756&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://regist2.virology-education.com/2011/6HEPPK/docs/08_Garg.pdf</a></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B4">Ref list</a>]</div><div id="body-link-popper-B9" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.<div class="authors">Josefsson M, Zackrisson AL, Ahlner J</div><div class="citation">Eur J Clin Pharmacol. 1996; 51(2):189-93.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8911887/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B9">Ref list</a>]</p></div><div id="body-link-popper-B13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Amlodipine has a minor effect on cyclosporine metabolism.<div class="authors">McGregor DO, Bailey RR, Robson RA</div><div class="citation">Clin Nephrol. 1997 Nov; 48(5):336.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9403222/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B13">Ref list</a>]</p></div><div id="body-link-popper-B22" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.<div class="authors">Williams D, Feely J</div><div class="citation">Clin Pharmacokinet. 2002; 41(5):343-70.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12036392/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B22">Ref list</a>]</p></div><div id="body-link-popper-B14" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Clinical pharmacokinetics of amlodipine.<div class="authors">Meredith PA, Elliott HL</div><div class="citation">Clin Pharmacokinet. 1992 Jan; 22(1):22-31.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1532771/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B14">Ref list</a>]</p></div><div id="body-link-popper-B15" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.<div class="authors">Murdoch D, Heel RC</div><div class="citation">Drugs. 1991 Mar; 41(3):478-505.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1711448/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B15">Ref list</a>]</p></div><div id="body-link-popper-B5" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.<div class="authors">Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, Grosskopf N, Zolopa AR, Gerber JG, Adult AIDS Clinical Trials Group A5159 Protocol Team</div><div class="citation">Clin Pharmacol Ther. 2005 Aug; 78(2):143-53.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16084849/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B5">Ref list</a>]</p></div><div id="body-link-popper-B10" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Clinical pharmacokinetics of atorvastatin.<div class="authors">Lennernäs H</div><div class="citation">Clin Pharmacokinet. 2003; 42(13):1141-60.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14531725/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B10">Ref list</a>]</p></div><div id="body-link-popper-B16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.<div class="authors">Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, Piliero PJ, Barditch-Crovo P, Fuchs E, Flexner C, Cameron DW</div><div class="citation">Antimicrob Agents Chemother. 2009 Oct; 53(10):4385-92.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19667285/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B16">Ref list</a>]</p></div><div id="body-link-popper-B19" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.<div class="authors">Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW</div><div class="citation">Clin Pharmacol Ther. 2004 Aug; 76(2):167-77.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B19">Ref list</a>]</p></div><div id="body-link-popper-B18" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.<div class="authors">Shitara Y</div><div class="citation">Drug Metab Pharmacokinet. 2011 Jun; 26(3):220-7.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21297316/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B18">Ref list</a>]</p></div><div id="body-link-popper-B7" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.<div class="authors">Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U</div><div class="citation">Drug Metab Dispos. 2000 Nov; 28(11):1369-78.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11038166/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B7">Ref list</a>]</p></div><div id="body-link-popper-B21" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">21. <span class="mixed-citation">
van Heeswijk R., et al.  2008.  <span class="ref-title">The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir, abstr. A-966</span>. 48th ICAAC, Washington, DC, 25–28 October 2008</span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#B21">Ref list</a>]</div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:21:18-04:00&amp;Host=ptpmc201">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC3187007_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC3187007_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC3187007_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187007/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=aac&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC3187007/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc201 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC3187007_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>